Physician profile
Michael C Kleinmann
NPI 1386620912
$50,267.55
in general payments reported to CMS, 2019-2025
30 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,412 · 2020: $2,233 · 2021: $13K · 2022: $22K · 2023: $4,396 · 2024: $6,361 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,011 · Food and Beverage: $2,104 · Travel and Lodging: $125 · Education: $50.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,011.00 |
| Food and Beverage | $2,103.52 |
| Travel and Lodging | $124.62 |
| Education | $50.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29,286.84 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $13,313.97 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $3,798.41 | 2019-2023 | Krystexxa |
| Amgen INC. | $1,108.85 | 2019-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $657.88 | 2019-2025 | Farxiga, Lokelma |
| Bard Peripheral Vascular, INC. | $355.52 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $180.20 | 2021-2024 | Lupkynis |
| Nxstage Medical, INC. | $179.60 | 2022-2023 | Liberty Select Cycler, Nxstage System One |
| Novartis Pharmaceuticals Corporation | $172.74 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $120.21 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $120.10 | 2019-2023 | Veltassa |
| Boston Scientific Corporation | $119.60 | 2019 | |
| Akebia Therapeutics INC | $113.73 | 2019-2024 | Auryxia, Vafseo |
| Alexion Pharmaceuticals, INC. | $111.23 | 2021-2025 | Ultomiris, Soliris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $105.61 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $66.05 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $60.54 | 2019-2023 | Velphoro |
| Daiichi Sankyo INC. | $46.47 | 2020-2025 | Injectafer |
| Glaxosmithkline, LLC. | $44.91 | 2021-2023 | Benlysta, Jesduvroq |
| Medtronic, INC. | $43.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.12 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $39.69 | 2023 | Acthar |
| Lilly USA, LLC | $37.69 | 2024-2025 | Jardiance |
| W. L. Gore & Associates, INC. | $26.86 | 2024 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Davol INC. | $25.56 | 2020 | |
| Mozarc Medical US LLC | $23.26 | 2025 | Palindrome |
| Lemaitre Vascular, INC. | $20.24 | 2025 | Artegraft Vascular Graft |
| Convatec INC. | $18.19 | 2025 | |
| Apellis Pharmaceuticals, INC. | $16.86 | 2025 | Empaveli |
| Bioventus LLC | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kleinmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.